Parameters | Intervention group (n = 27) | Control group (n = 23) | p-value |
---|---|---|---|
Gender: female/male, n (%) | 22 (81)/5 (19) | 21 (91)/2 (9) | 0.429 |
Age, years | 56.0 (41.0–68.0) | 58.0 (52.0–65.0) | 0.513 |
Clinical features | |||
Disease duration, years | 6.0 (2.0–9.4) | 2.8 (1.4–8.3) | 0.266 |
IIM subtype, n (%): PM/DM/IMNM | 12 (44)/10 (37)/5 (19) | 10 (44)/11 (48)/2 (8) | 0.064 |
IIM-associated symptoms, n (%): | |||
MW/D/SR/MH/ | 27 (100)/5 (19)/2 (7)/1 (4)/ | 23 (100)/7 (30)/4 (17)/3 (13)/ | 1.000/0.319/0.379/0.306/ |
RP/A/ILD/CI | 3 (11)//1 (4)/9 (33)/4 (15) | 7 (30)//1 (4)/7 (30)/5 (22) | 0.081/1.000/1.000/0.477 |
MMT-8 total score | 56.0 (48.0–65.0) | 64.0 (55.0–71.0) | 0.024 |
MITAX | 0.2 (0.1–0.3) | 0.2 (0.1–0.4) | 0.120 |
MDI extent | 0.1 (0.0–0.1) | 0.1 (0.0–0.1) | 0.355 |
Laboratory features | |||
Autoantibodies, n (%): | |||
ANA/Mi-2/TIF1/MDA5/ | 17 (63)/2 (7)/0 (0)/0 (0)/ | 14 (61)/1 (4)/2 (9)/1 (4)/ | 1.000/1.000/0.186/0.437/ |
SAE/NXP2/SRP/HMGCR/Jo-1/ | 0 (0)/2 (7)/1 (4)/3 (11)/3 (11)/ | 1 (4)/1 (4)/2 (8)/0 (0)/7 (30)/ | 0.437/1.000/0.574/1.000/0.081/ |
PM-Scl/snRNP/Ku/Ro | 2 (7)/2 (7)/2 (7)/11 (41) | 2 (9)/0 (0)/0 (0)/8 (35) | 1.000/1.000/1.000/0.497 |
CRP, mg/L | 3.0 (1.7–4.6) | 4.1 (1.4–8.2) | 0.403 |
ESR, mm/h | 13.0 (7.0–26.0) | 15.0 (9.0–30.0) | 0.550 |
CK, μkat/L | 4.0 (1.8–8.9) | 1.3 (0.8–3.9) | 0.005 |
LD, μkat/L | 4.0 (3.5–4.9) | 3.7 (3.4–4.7) | 0.626 |
Myoglobin, μg/L | 112.3 (67.0–299.5) | 78.0 (47.6–128.2) | 0.108 |
Current treatment | |||
Prednisone equivalent dose, mg/day | 6.0 (1.3–10.0) | 15.0 (5.0–30.0) | 0.021 |
MTX/CPA/AZA/CSA/ | 10 (37)/0 (0)/7 (26)/4 (15)/ | 7 (30)/1 (4)/2 (9)/2 (9)/ | 0.767/0.460/0.152/0.674/ |
LEF/MMF/SAS/HQ/TAC/ | 0 (0)/2 (7)/1 (4)/0 (0)/1 (4)/ | 2 (9)/0 (0)/0 (0)/1 (4)/0 (0)/ | 0.207/0.493/1.000/1.000/1.000/ |
RTX/IVIg, n (%) | 0 (0)/0 (0) | 0 (0)/0 (0) | 1.000/1.000 |